Project Grant R01AI187821
Award Date
5/13/25
Completion Date
4/30/30
Dollars Obligated
$393K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $684,206 to the University of Maryland, Baltimore to develop nanoparticle-based immunotherapies for the treatment of sepsis. The objectives are to evaluate the immunomodulatory properties of these nanoparticles, identify their cellular and molecular mechanisms of action, and determine the optimal therapeutic window...
This Project Grant award, totaling $237,518, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research aims to identify synergistic combinations of aminoglycoside antibiotics that can effectively treat multidrug-resistant Gram-negative bacterial infections while also suppressing the emergence of resistance and limiting toxicity. Key objectives include: 1) Screening diverse...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to President and Fellows of Harvard College to conduct research focused on developing novel antibiotics to address the challenge of multi-drug resistant bacterial pathogens. The research aims to synthesize and evaluate new antibiotic compounds that target the lipoprotein transport pathway in...
This $2,308,174 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop new antibiotic combinations and dosing strategies to combat carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The award, which runs from August 8, 2024 to May 31, 2029, involves three projects and three cores conducted by the University of Florida, the...
This federal Project Grant award of $299,163 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel antimicrobial approach that combines endolysin proteins with self-replicating mRNA (RepRNA) delivery using lipid nanoparticles. The key objectives of this Phase I proof-of-concept study are to: 1) evaluate whether RepRNA can successfully express a lysin that targets vancomycin-resistant...
This $569,210 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to structurally and functionally characterize three key proteins responsible for antimicrobial peptide/colistin resistance in Gram-negative bacteria, including high-threat pathogens like carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae. The research aims to develop...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $802,798 to The Research Foundation For The State University Of New York (RF SUNY) to develop a novel class of antimicrobial agents called "Biamyxins" (BMX) for treating multidrug-resistant Gram-negative bacterial infections. The funding supports further optimization of the lead BMX compound...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned for-profit company located in Santa Barbara, California. The grant supports the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target bacterial membranes to combat antimicrobial resistance. The key objectives are to assess...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Rowan University a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel, daptomycin-inspired antimicrobial peptides using non-canonical amino acids. The goal is to create peptide molecules that replicate the key antimicrobial mechanisms of daptomycin, such as calcium binding and lipid membrane disruption, while improving resistance to degradation and enhancing the...